Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 5.62 -7.11% -0.43
EGRX closed down 7.11 percent on Monday, March 18, 2024, on 58 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Pocket Pivot Bullish Swing Setup -7.11%
Outside Day Range Expansion -7.11%
20 DMA Resistance Bearish -6.49%
Earnings Movers Other -1.92%
Fell Below 20 DMA Bearish -4.26%

   Recent Intraday Alerts

Alert Time
Outside Day about 16 hours ago
Down 5% about 16 hours ago
Fell Below Lower Bollinger Band about 16 hours ago
Fell Below Previous Day's Low about 16 hours ago
Lower Bollinger Band Support about 16 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Eagle Pharmaceuticals, Inc. Description

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Lymphoma Small Cell Lung Cancer Stroke Lung Cancer Toxicology Chronic Lymphocytic Leukemia Lymphocytic Leukemia Organic Chemistry Angioplasty Percutaneous Thrombocytopenia Heparin Treatment Of Chronic Lymphocytic Leukemia Nitrogen Mustards

Is EGRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.4
52 Week Low 4.1
Average Volume 247,929
200-Day Moving Average 12.28
50-Day Moving Average 5.54
20-Day Moving Average 6.14
10-Day Moving Average 6.06
Average True Range 0.45
RSI (14) 44.44
ADX 14.26
+DI 16.76
-DI 21.21
Chandelier Exit (Long, 3 ATRs) 5.45
Chandelier Exit (Short, 3 ATRs) 6.57
Upper Bollinger Bands 6.65
Lower Bollinger Band 5.62
Percent B (%b) 0.0
BandWidth 16.82
MACD Line 0.05
MACD Signal Line 0.13
MACD Histogram -0.0825
Fundamentals Value
Market Cap 72.99 Million
Num Shares 13 Million
EPS 0.85
Price-to-Earnings (P/E) Ratio 6.61
Price-to-Sales 0.29
Price-to-Book 0.27
PEG Ratio 0.91
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.60
Resistance 3 (R3) 6.68 6.43 6.43
Resistance 2 (R2) 6.43 6.19 6.39 6.38
Resistance 1 (R1) 6.03 6.03 5.91 5.95 6.32
Pivot Point 5.78 5.78 5.72 5.74 5.78
Support 1 (S1) 5.38 5.54 5.26 5.30 4.92
Support 2 (S2) 5.13 5.38 5.09 4.86
Support 3 (S3) 4.73 5.13 4.81
Support 4 (S4) 4.65